Background
==========

A conserved set of receptors called pattern-recognition receptors has immense importance in the innate immune system. The role of TLRs, members of mammalian pattern-recognition receptors, has been elaborated in the recent years \[[@B1]-[@B5]\]. They are the key components of pathogen recognition mechanism initiating inflammatory responses brought about by microbes or microbial cell components \[[@B6],[@B7]\]. TLR family possesses 14 distinct members identified so far, expressed by epithelial and endothelial cells as well as leukocytes. TLRs are type-I transmembrane receptors composed of an ectodomains, a short transmembrane region, and an intracellular signaling domain that shares homology with that of the IL-1 receptor \[[@B8]\]. TLR mediated cellular activation occurs following the recognition of specific microbial components by the ECD \[[@B8]\]. These receptors act as the sensors for viral, bacterial and fungal structures, for example, TLR3 recognizes viral dsDNA \[[@B9]\], TLR7 and TLR8 recognize the ssRNA \[[@B10]-[@B12]\], TLR5 triggers immune signal by detecting flagellin, and CpG DNA is the ligand for TLR9 \[[@B13],[@B14]\]. Toll like receptors focused in this study, TLR1, TLR2 and TLR4, recognize bacterial cell components. TLR2 has shown to mediate the innate immune response to ligands derived from *Mycoplasma*, *Borrelia, Treponema, Chlamydia*, yeasts and parasites \[[@B15]-[@B20]\]. TLR2 and TLR4 are critical in the immune response against Gram positive and negative bacteria \[[@B21]\]. Indeed, TLR1 and TLR6 in association with TLR2 (TLR1-TLR2 and TLR2-TLR6 heteromers) recognize a variety of bacterial cell wall components \[[@B22]-[@B25]\].

Mutations in the coding region of human TLRs are linked with the altered PAMP recognition ability, signal transduction or innate immune activation in general \[[@B19],[@B26]-[@B30]\]. Mutations in TLR1 gene are associated with the variation in the immune response to lipopeptides \[[@B27]\], increased susceptibility to invasive aspergillosis \[[@B31]\] or impaired innate immune sensing of microbial cell wall components \[[@B32]\]. TLR2 and TLR4 gene polymorphisms are often linked with increased risk to infections like tuberculosis \[[@B15],[@B33]\], *Mycobacterium leprae*\[[@B34],[@B35]\], pneumococci or malaria \[[@B30],[@B36]\], urinary tract infections \[[@B37]\] and disease conditions like periodontitis \[[@B38]\], acute rheumatic fever \[[@B39]\] and Crohn\'s disease \[[@B40]\].

The aim of the study was to screen the ovine population for the mutations in TLR1, TLR2 and TLR4 genes, and to assess their possible association with susceptibility to MAP.

Results
=======

Presence of MAP in the sheep population
---------------------------------------

82 sheep (11.3%) were found to be infected with MAP when tested with ELISA as well as *IS900*based PCR. MAP infected (n = 82) and non-infected (n = 838) sheep were studied further for the presence of TLR mutations.

TLRs gene mutations and MAP infection
-------------------------------------

None of the earlier cited mutations in TLR2 and TLR4 (TLR2 -- Pro681His, Arg677Trp, Arg753Gln, and TLR4 -- Asp299Gly, Thr399Ile) were found in the sheep population. However, the sequence analysis revealed novel mutations in the ovine TLR2 and TLR4 (Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}). We found novel mutation Phe670Leu in TLR2 gene in 56 sheep infected with MAP. 25% of the subjects carrying this mutation in heterozygous state (OR -- 4.5) and 7.6% subjects carrying this mutation in homozygous state (OR -- 1.1) were MAP infected (Table [2](#T2){ref-type="table"}). Another mutation in TLR2 gene at the base pair 2037 (T to C) exchanging leucine against proline (679^th^amino acid residue) was found in 54 subjects infected with MAP. Both these mutations are located in highly conserved region of TLR2 gene near the known mutation Arg677Trp.

###### 

Missense mutations in the ovine TLR1

                                  **Wild type frequency**   **Frequency of mutation in heterozygous state**   **Frequency of mutation in homozygous state**
  --------- --------------------- ------------------------- ------------------------------------------------- -----------------------------------------------
  418A\>G   Lys140Glu             0.997 (11.4%)             0                                                 0.002 (0%)
  431A\>T   Asn144Ile             0.997 (11.4%)             0                                                 0.002 (0%)
  448A\>G   Ser150Gly             0.897 (8.38%)             0                                                 0.10 (43.2%, ***9.08***)^1^
  508T\>C   Ser170Pro             0.997 (11.4%)             0                                                 0.002 (0%)
  517G\>R   Glu173 \[Lys, Glu\]   0.897 (8.38%)             0.10(43.2%, ***9.08***)                           0
  601A\>T   Ile201Phe             0.997 (11.4%)             0                                                 0.002 (0%)
  603T\>C   Ile201Phe             0.997 (11.4%)             0                                                 0.002 (0%)
  658A\>G   Val220Met             0.897 (8.38%)             0                                                 0.102 (43.2%, ***9.08***)

^1^The first value in the parenthesis indicate the percentage of animals infected with MAP that carries given point mutation, the second value (***bold-italics***) is the Odd\'s ratio (OR) indicating the possible linkage between the point mutation and increased susceptibility to MAP infection.

###### 

Missense mutations in the ovine TLR2

                                   **Wild type frequency**   **Frequency of mutation in heterozygous state**   **Frequency of mutation in homozygous state**
  ---------- --------------------- ------------------------- ------------------------------------------------- -----------------------------------------------
  1985A\>W   Glu662 \[Glu, Val\]   0.94 (21%)                0.06 (4.7%)                                       0
  2008A\>Y   Phe670 \[Leu, Phe\]   0.55 (6.5%)               0.25 (25%, ***4.5***)                             0.20 (7.6%, ***1.1***)^1^
  2012A\>M   Lys671 \[Asn, Thr\]   0.99 (11.4%)              0.01 (0%)                                         0
  2013G\>T   Lys671 \[Asn, Thr\]   0.99 (11.4%)              0                                                 0.01 (0%)
  2028G\>S   Lys676 \[Asn, Lys\]   0.99 (11.4%)              0.01 (0%)                                         0
  2037T\>Y   Leu679Phe             0.57 (6.3%)               0.35 (19.9%, ***2.01***)                          0.08 (10.3%, ***1.36***)
  2038G\>A   Val680Ile             0.998(11.4%)              0                                                 0.002 (0%)
  2040C\>T   Val680Ile             0.998(11.4%)              0                                                 0.002 (0%)
  2090G\>R   Arg697 \[His, Arg\]   0.997 (12.9%)             0.001 (0%)                                        0.003 (0%)
  2111C\>y   Ser704 \[Ser, Leu\]   0.998 (11.4%)             0.002 (0%)                                        0
  2117G\>A   Ser706Asn             0.995 (11.4%)             0                                                 0.005 (0%)
  2126G\>A   Arg709Lys             0.997 (11.4%)             0                                                 0.003 (0%)
  2233G\>R   Val745 \[Ile, Val\]   0.995 (11.4%)             0.001 (0%)                                        0.004 (0%)
  2276G\>A   Arg759Lys             0.995 (11.4%)             0                                                 0.005 (0%)
  2296G\>A   Val766Thr             0.998 (11.4%)             0                                                 0.002 (0%)
  2297T\>C   Val766Thr             0.998 (11.4%)             0                                                 0.002 (0%)

^1^The first value in the parenthesis indicate the percentage of animals infected with MAP that carries given point mutation, the second value (***bold-italics***) is the Odd\'s ratio (OR) indicating the possible linkage between the point mutation and increased susceptibility to MAP infection.

###### 

Missense mutations in the ovine TLR4

                                   **Wild type frequency**   **Frequency of mutation in heterozygous state**   **Frequency of mutation in homozygous state**
  ---------- --------------------- ------------------------- ------------------------------------------------- -----------------------------------------------
  881G\>R    Ser294 \[Ser, Asn\]   0.84 (12.6%)              0.14 (5.7%)                                       0.02 (0%)
  883A\>R    Lys295 \[Lys, Glu\]   0.84 (12.6%)              0.14 (5.7%)                                       0.02 (0%)
  892T\>Y    Trp298 \[Trp, Arg\]   0.84 (12.6%)              0.14 (5.7%)                                       0.02 (0%)
  934G\>A    Val312Met             0.998 (11.4%)             0                                                 0.002 (0%)
  955T\>C    Ser319Pro             0.998 (11.4%)             0                                                 0.002 (0%)
  1029T\>K   Asp343 \[Glu, Asp\]   0.993 (11.4%)             0.007 (0%)                                        0
  1032G\>S   Lys344 \[Asn, Lys\]   0.87 (12.6%)              0.12 (3.5%)                                       0.012 (0%)
  1045A\>G   Lys349Glu             0.998 (11.4%)             0                                                 0.002 (0%)
  1052G\>R   Arg351 \[His, Arg\]   0.87 (12.3%)              0.12 (5.8%)                                       0.012 (0%)
  1066T\>Y   Phe356 \[Leu, Phe\]   0.36 (14.3%)              0.52 (8.2%)                                       0.12 (16.4%, ***1.64***)^1^
  1088A\>R   Asp363 \[Asp, Gly\]   0.84 (12.5%)              0.14 (5.7%)                                       0.02 (0%)
  1091T\>Y   Val364 \[Val, Ala\]   0.84 (12.5%)              0.14 (5.7%)                                       0.02 (0%)
  1097C\>S   Thr366 \[Thr, Ser\]   0.84 (12.5%)              0.14 (5.7%)                                       0.02 (0%)
  1166G\>S   Ser389 \[Thr, Ser\]   0.998 (11.4%)             0.001 (0%)                                        0
  1183G\>K   Asp395 \[Asp, Tyr\]   0.84 (12.5%)              0.14 (6%)                                         0.002 (0%)

^1^The first value in the parenthesis indicate the percentage of animals infected with MAP that carries given point mutation, the second value (***bold-italics***) is the Odd\'s ratio (OR) indicating the possible linkage between the point mutation and increased susceptibility to MAP infection.

Novel mutation in TLR4 gene associated with the increased susceptibility to MAP infection was located at the base pair T1066C exchanging phenylalanine against leucine (OR -- 1.64). Other mutations found in TLR2 and TLR4 genes in this study (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}) had no association with the increased susceptibility to MAP infection.

Two mutations (Ser150Gly and Val220Met) in TLR1 gene were found in 74 subjects, of that 32 sheep (43.2%) were infected with MAP. Both these mutations occurred simultaneously in all 74 subjects. Apart from these two mutations we found novel mutations in TLR1 at the base pairs: 418 (A to G), 431 (A to T), 508 (T to C), 601 (A to T) and 603 (T to C) (Table [1](#T1){ref-type="table"}).

TLR expression in mutant moDCs
------------------------------

Representative sheep (n = 6 per mutation;*mutant moDCs*), not infected with MAP but carrying mutations associated with MAP infection were included in this phase of the study. Healthy sheep without TLR mutations (n = 6; *wild type moDCs*) were targeted for TLR mRNA expression as a control. We observed 3--6 fold increase in the TLRs expression in activated moDCs as compared to the non-activated control moDCs (Figure [1](#F1){ref-type="fig"}). However, when mutant and wild type moDCs were challenged with LPS or MAP whole cell lysate, the antigen dependent induction of TLRs was not observed (P \> 0.05; Figure [1](#F1){ref-type="fig"}). Expression of β-actin was unchanged throughout the TLR mRNA expression experiments (data not shown).

![**Activation of TLRs in the mutant and wild type (WT) moDCs challenged with LPS or MAP whole cell lysate**. Relative fold expressions of TLR mRNA in unstimulated (dark bars) and activated mutant as well as wild type moDCs. The cells were either activated by LPS (shaded bars) or MAP whole cell lysate (white bars).](1471-2156-10-21-1){#F1}

TLR mutations and cytokine mRNA production
------------------------------------------

IFN-γ, IL-10 and IL-12 were abundantly expressed cytokines in the wild type moDCs when challenged with LPS and MAP whole cell lysate. The cytokines expression, except IL-4, in challenged wild type moDCs was 6 to 9 fold higher than in non-challenged moDCs (Figure [2](#F2){ref-type="fig"}). In general, MAP cell lysate caused higher cytokine response in the moDCs than LPS. Expression of IL-8 was lower than other abundantly expressed ILs, whereas IL-4 was neither detected in ovine wild type nor in mutant moDCs (Figure [2](#F2){ref-type="fig"}).

![**Expression of cytokine mRNA in the activated mutant and wild type moDCs**. Comparative relative fold expressions of cytokine mRNA in unstimulated (dark horizontal bars) and activated mutant and wild type moDCs. The cells were either activated by LPS (shaded horizontal bars) or MAP whole cell lysate (white horizontal bars). β-actin served as a control gene. Significant difference in the cytokine mRNA expression between stimulated WT and mutant moDCs is depicted by -- \* (p \< 0.05).](1471-2156-10-21-2){#F2}

Expression of IL-10 in the challenged TLR1 mutant (Gly150, Met220) moDCs was significantly lower (P \< 0.05; Figure [2](#F2){ref-type="fig"} panel C) than in the challenged wild type moDCs. This cytokine was also under expressed in the mutant moDCs carrying TLR2 Leu670 mutation (Figure [2](#F2){ref-type="fig"} panel C). Another two cytokines, IFN-γ and IL-12, were under expressed in the mutant moDCs carrying TLR1 (Gly150, Met220) and TLR2 (Leu670) mutations compared with the wild type moDCs (Figure [2](#F2){ref-type="fig"} panel D and E). Interestingly IL-8 mRNA expression was unchanged in TLR1 mutant moDCs, but significantly lowered (P \< 0.05, Figure [2](#F2){ref-type="fig"} panel B) in TLR2 Leu670 moDCs. No altered cytokine expression was noticed in the challenged moDCs carrying TLR2 Phe679 and TLR4 Leu356 mutations (Figure [2](#F2){ref-type="fig"}).

TLR1 and TLR4 LRR motifs: *In silico*analysis
---------------------------------------------

TLR gene family is conservative and show certain homology between human and ovine TLR genes (TLR1 \~75%, TLR2 \~82 and TLR4 \~80). The central core of regular LRR motif is LxxLxLxxNxL, wherein \'x\' is any amino acid, \'L\' is Leu, Ile, Val or Phe, and \'N\' is Asn, Thr, Ser or Cys. Certain irregularities were observed within the LRR motifs of TLR1 (LRR8 and LRR11) and TLR4 (LRR13 and LRR14) (Figure [3](#F3){ref-type="fig"} panel A and B). A central part of ovine TLR1 ectodomain (LRR10) was prone to missense mutations and more irregular than other LRRs. TLR1 mutations Gly150 and Met220, causing hyporesponsiveness to MAP infection, were located within the extra-LRR region and intra-LRR motif respectively (Figure [3](#F3){ref-type="fig"} panel A). Met220 mutation was found in LRR10 motif at the 9^th^amino acid position (LxxLxLxx**[N]{.ul}**^9th^xL).

![**Comparative amino acid sequences of human and sheep LRR motifs of TLR1 and TLR4**. ***A (TLR1) and B (TLR4)***. Irregularities in the LRR motifs (LxxLxLxxNxL) are depicted with underlined letters; differences between human and ovine LRR domains are indicated with the dark ovals and mutations TLR1- Ser150Gly and Val220Met are highlighted with the dark squares. Known mutations in human TLR4 -- Asp299Gly and Thr399Ile are located in extra LRR motif (\*, B).](1471-2156-10-21-3){#F3}

We also present LRR motif structure of TLR4 ECD spanning earlier described Asp299Gly and Thr399Ile mutations. Both mutations were found in extra LRR region (Figure [3](#F3){ref-type="fig"} panel B) in human TLR4. In the sheep population TLR4 Asp299Gly and Thr399Ile mutations were absent; however, the amino acid position 299 was occupied by asparagine and 399 by theronine.

Discussion
==========

Recent studies have reported the involvement of TLRs in the innate immune response against MAP \[[@B41],[@B42]\]. Mycobacterial cell wall components like lipomannan, lipoarabinomannan, phosphatidylinositol dimannoside and a 19-kDa lipoprotein are the agonists for the TLR1 and TLR2 receptors \[[@B21],[@B43]-[@B45]\], while TLR4 recognizes live *M. tuberculosis*\[[@B46]\]. TLRs mediated downstream pathway leads to the up-regulation of interleukins, chemokines, costimulatory molecules, adhesions and pro-inflammatory/anti-inflammatory cytokines \[[@B47],[@B48]\]. Activation of TLRs not only direct the phagocytic cells to process and present the antigens but also induce their self expression \[[@B47]\]. TLR dependent activation of macrophages leads to the phagocytosis and secretion of inflammatory modulators, whereas activated dendritic cells are directed towards the uptake, its processing and presentation of the antigen to T cells \[[@B49]\].

The heterozygous variant may give ambiguous results. Neither the hyporesponsiveness, nor the reduced cytokine response to TLR agonists was observed in heterozygous TLR4-Asp299Gly \[[@B50]-[@B52]\] and heterozygous TLR2-Arg753Gln cells \[[@B15],[@B33]-[@B35]\]. Hence, in the present study the *in vitro*challenging was carried out only in moDCs carrying mutations in homozygous state.

In this study, IL-12, IFN-γ and IL-10 were expressed abundantly in the activated wild type moDCs. Others \[[@B47],[@B49]\] have reported that moDCs primarily produce IL-12 upon triggering by the TLR agonists, while macrophages produce IL-10. However, we found no significant difference between the expression levels of IL-12 and IL-10 mRNAs in the activated wild type moDCs. In line with the previous reports \[[@B47],[@B53]\] we also found mixed Th1/Th2 cytokine response in moDCs to TLR agonists. IL-12 and IFN-γ are the Th1 cytokines while IL-10 belongs to the Th2 class. IL-4 was the least expressed Th2 interleukin in the activated wild type as well as in mutant moDCs in this study. Earlier reports \[[@B54],[@B55]\] suggest the structural and functional similarities between IL-13 and IL-4. The lowest expression of IL-4 may be because of its substitution by IL-13. It is important to note that IL-8 mRNA expression was significantly hindered in the activated mutant moDCs possessing TLR2 Leu670 mutation, but not in the activated mutant moDCs carrying TLR1 mutations. This indicates that IL-8 expression might be TLR2 dependent. Supportive data was published earlier, wherein micrococci and peptidoglycan induced transcription of IL-8 in the cells expressing TLR2 only \[[@B56]\].

Human and ovine TLR1 ECD consist of 20 predicted LRRs that take part in the mycobacterial PAMP recognition \[[@B57]\]. The central region of the extracellular domain of human TLR1 (LRR9 to LRR12) is necessary for the sensing of bacterial lipopeptides \[[@B32]\]. We (unpublished data, bovine TLR1 LRR motif analysis) and others (human TLR1) \[[@B51]\] have found that the central part of TLR1 ECD (LRR9 to LRR11) is more irregular and prone to missense mutations. In this study, novel mutation Val220Met was observed in LRR10 motif at the 9^th^amino acid position (Figure [3A](#F3){ref-type="fig"}). The presence of methionine in this position may disrupt hydrogen bonds in the LRR loop structure that may cause reduced recognition of PAMPs \[[@B51]\]. The association between mutation at 9^th^amino acid position in the human TLR-LRR motif and poorly-differentiated gastric adenocarcinomas was reported recently \[[@B58]\]. The increased incidence of MAP infection in sheep bearing Val220Met mutation (43.2%; OR -- 9.08) was also observed in this study. Significant reduction (P \< 0.05, Figure [2](#F2){ref-type="fig"}) in the cytokine response to TLR1 agonists (LPS and MAP lysate) in moDCs carrying 220Met (LRR10) and 150Gly (two residues upstream to LRR8) confirms the adverse effect of mutations in the central ECD of TLR1.

In the case of TLR2, the TIR domain is crucial as it forms a TIR-TIR dimerized platform (TLR1-TLR2 and TLR2-TLR6), which promote homotypic protein-protein interactions and further downstream signaling \[[@B59]\]. Hindered expression of the IFN-γ, IL-8 and IL-12 in the moDCs carrying homozygous 670Leu (Figure [2](#F2){ref-type="fig"} panel B, D and E) can be due to the impaired dimerization of TLR2-TIR domain with its counterparts. Similar impediment in the IL-12, IL-8 and IFN-γ production was reported earlier in Arg677Trp or Arg753Gln mutants \[[@B59]-[@B65]\]. Other crucial residues in human TLR2-TIR domain (713Ser, 730Asp, 748Arg, 749Phe and 752Leu) were reported previously \[[@B61]\].

Mutations in the extra-LRR region may also impede the pattern recognition. 3D structure of the TLR ECD has demonstrated that LRR forms a loop and the juxtaposition of several loops produce solenoid-like structure \[[@B51]\]. The LRR consensus motif forms the inner core of horseshoe structured ECD, while extra LRR regions forms convex surface. Irregularities and/or mutations in the convex surface, for example mutation in 4^th^residue downstream from LRR motif, may affect PAMP binding onto the TLR horseshoe. The well known human TLR4 mutation, Asp299Gly, is one of the best examples of the mutation at 4^th^residue downstream from LRR11 (Figure [3B](#F3){ref-type="fig"}).

Conclusion
==========

Ser150Gly and Val220Met mutations in TLR1, and Phe670Leu in TLR2 gene were found to cause hindrance in mycobacterial PAMPs recognition. These novel mutations found in TLRs may pose a risk that increases the susceptibility to mycobacterial infection.

Methods
=======

Animals
-------

720 pure bred Tsigai sheep, either healthy (healthy cohort) or showing clinical symptoms of paratuberculosis (diseased cohort) were included in this study. The genetic diversity, population structure of this breed is described in details recently \[[@B66]\]. The sheep were from four farms located in the same geographic area (eastern Slovakia). These farms were chosen for the present study because of the high incidence (10--18%) of MAP recorded during paratuberculosis surveillance in the years 2004--2006 (unpublished data). Animals with weight loss and/or chronic diarrhea formed a cohort suspected of paratuberculosis. At least 7 -- 8 apparently healthy animals that had close contact with suspected animals were also included in the study. In this way we assured the equal probability of MAP infection on the studied animals. The animal history was recorded and 5--10 ml of the blood (in duplicate) was collected for the serum and buffy coat separation.

Detection of MAP
----------------

Animals were screened for the presence of anti-MAP antibodies in serum as well as for the presence of *IS900*element of MAP in the buffy coat. Antibodies were detected with Pourquier ELISA paratuberculosis kit (Institute Pourquier, France, <http://www.institut-pourquier.fr>). *IS900*based nested PCR for MAP detection was designed as described previously \[[@B67]\]. The method, sensitivity and specificity of *IS900*based PCR are discussed in detail in our previous work \[[@B67]\]. On the basis of PCR and ELISA results, animals were grouped into MAP positive and negative cohorts, and cohorts were subjected to mutation detection in TLR genes.

Construction of primers and PCR for amplification of TLR gene fragments
-----------------------------------------------------------------------

ECD of the TLR1 was targeted for mutation detection. Primers were designed (DNASTAR) to amplify a gene fragment covering LRR8 to LRR11 (Table [4](#T4){ref-type="table"}). Conditions for PCR were: initial denaturation at 95°C for 3 min, followed by 35 cycles of 94°C for 1.0 min, 52°C for 1 min 20 sec, 72°C for 1.0 min with final extension at 72°C for 10 min. Primers for TLR2 were constructed to amplify gene fragments covering earlier reported Pro681His, Arg677Trp and Arg753Gln mutations \[[@B15],[@B39]\] located in Toll/Interleukin-1 receptor (TIR) domain. Primers designed for TLR4 spanned both previously described major polymorphism sites, Asp299Gly and Thr399Ile \[[@B40]\] located in ECD (LRR11 to LRR16). Nucleotide sequences of TLR2 and TLR4 primers are depicted in Table [4](#T4){ref-type="table"}. PCR conditions for TLR2 gene were: initial denaturation at 94°C for 3 min, followed by 35 cycles of 94°C for 60 sec, 56°C for 45 sec, and 72°C for 60 sec with final extension at 72°C for 10 min. The cycling conditions for TLR4 were similar to TLR2 except annealing temperature (57°C).

###### 

Primers used in this study

  -------------------------------------------------------------------------------------------------------------------
  **Gene**                  **Sequence (5\'-3\')**        **Amplicon length (bp)**   **Annealing temperature (°C)**
  ------------------------- ----------------------------- -------------------------- --------------------------------
  *IS900*- MAP (external)   F-AGGGTGTTCGGGGCCGTCGCTTAG\   406                        56.5
                            R-TGAGGTCGATCGCCCACGTGACCT                               

  *IS900*-MAP (internal)    F-ATGTGGTTGCTGTGTTGGATGG\     298                        63.0
                            R-CCGCCGCAATCAACTCCAG                                    

  TLR1                      F-GGAGATACTTATGGGGAAAGAGAA\   402                        52.0
                            R-GTGTATAGACAAGGCCTTCAGTGA                               

  TLR2                      F-CAGGAGCTGGAGCACTTGTACC\     362                        56.0
                            R-GTCTCATCCACGGGCCAGACCA                                 

  TLR4                      F-GGGACTGTGCAACCTGACCA\       434                        53.0
                            R-GCTCTAAGCCCATGAAGTTTGAA                                

  IL-4                      F-CCCAGCGCTGGTCTGCTTACT\      283                        57.4
                            R-GCTTGCCAGGCTGCTGAGATT                                  

  IL-8                      F-TTGGCCGCTTTCCTGCTCT\        249                        55.2
                            R-AAATGCCTGCACAACCTTCTGC                                 

  IL-10                     F-AGCCGAGATGCCAGCACCCTGTC\    293                        61.0
                            R-AGCTTCTCCCCCAGCGAGTTCACG                               

  IL-12p35                  F-GAGCCTGCCCACCACCACA\        226                        56.4
                            R-GGAAGCCAGGCAACTCTCATT                                  

  IFN-γ                     F-CTAAGGGTGGGCCTCTTTTCTC\     237                        53.2
                            R-CATCCACCGGAATTTGAATCAG                                 

  β-actin                   F-ACTGGGACGACATGGAGAG\        568                        54.0
                            R-AGGAAGGAAGGCTGGAAGAG                                   
  -------------------------------------------------------------------------------------------------------------------

Single strand conformational polymorphism analysis (SSCP)
---------------------------------------------------------

Briefly, 5 μl of amplified product was mixed with equal amount of loading dye (98% formamide, 10 mM EDTA, 0.025% bromophenol blue, 0.025% xylene-cyanol), subjected to denaturation at 95°C for 10 min and then cooled rapidly on ice. Denatured single-stranded amplimers were loaded onto 6% acrylamide/bisacrylamide (37.5:1, v/v; Bio-Rad) gels. Electrophoresis was performed using 200 V at 8°C in 0.5% TBE buffer for 20 hours in the electrophoresis chamber (Ingeny, The Netherlands). Gels were silver-stained. Samples were grouped based on SSCP profiles by using Gel-Scan software (BioSciTec, Germany).

DNA Sequencing
--------------

Representative samples from each SSCP genotype were sequenced on an Avant3100 sequencer (Applied Biosystem). The sequences were aligned, then checked for mutations and validated using SeqScape v.2.1 software (Applied Biosystem). Sequences were submitted to the GeneBank (USA) under the accession numbers [EF681961](EF681961) to [EF681970](EF681970). The SNPs were submitted to dbSNP (Genebank) database under the accession numbers: [76880840](76880840) to [76880850](76880850) and [76878648](76878648) to [76878669](76878669).

In-vitro treatment of moDCs with LPS or MAP whole cell lysate
-------------------------------------------------------------

Representative sheep (n = 6 per mutation) which were not infected with MAP but carrying mutations associated with MAP infection in the homozygous state (depicted in tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}) were included in this phase of the study. Healthy subjects (n = 6) without mutations in TLR were served as controls. moDCs were generated from peripheral blood mononuclear cells as described previously \[[@B47]\] in Nunc 6-well tissue culture plates (approximately 5 × 10^5^cells/well in 2 ml of cell suspension). moDCs were either treated with 100 μl of LPS (1 g/ml; Sigma) or 100 μl of MAP whole cell lysate (\~890 μg/ml of protein concentration). As a negative control (no cell activation) moDCs were kept untreated. Cells were incubated at 37°C for 4 h in 5% CO~2~incubator, washed and total RNA was extracted using Purezol RNA isolation kit (Bio-Rad). Complementary DNA (cDNA) was synthesized by using iScript cDNA synthesis kit (Bio-Rad). The cDNA was used for real time PCR to examine the effect of treatment of moDCs on cytokine and TLR mRNA expression. moDCs with or without mutations are designated as mutant moDCs and wildtype moDCs respectively in this report.

Real time PCR for quantification of TLRs and cytokines mRNA expression
----------------------------------------------------------------------

Primers used to amplify cDNAs of the TLRs, cytokines as well as housekeeping gene are depicted in the Table [4](#T4){ref-type="table"}. PCR reactions were carried out in triplicate by using iQ SYBR green super mix Kit (Bio-Rad). All PCRs were followed by melting curve analysis (iQ5 thermocycler, Bio-Rad). Melting curve analysis was used to confirm the amplified product purity (confirmation of no non-specific amplicons). For the comparison of gene expression the ΔCt method (relative quantity gene expression) was applied using iQ5 software (Bio-Rad).

In silico ovine LRR motif analysis
----------------------------------

The ovine TLR nucleotide sequences obtained in this study were aligned by ClustalW multiple alignment method (DNASTAR software), translated into putative amino acids and consensus sequences were obtained (BioEdit software). LRR motifs were outlined according to the method described earlier \[[@B68]\] using PFAM and SSpro4.0 servers \[[@B69]\].

Statistical analysis
--------------------

The possible linkage between mutation and increased MAP infection was calculated by Odd\'s ratio (OR) (Win-episcope software). Relative quantity gene expression (ΔCt) was determined as follows -

Where E = efficiency of primer set (% efficiency \* 0.01+1), *Ct(control)*= Average Ct for control, and *Ct(sample)*= Average Ct for the sample. Paired t-test (STATGRAPHICS plus 5.1) was used to assess the mutation as well as stimulant (MAP lysate or LPS) dependent variations in cytokine mRNA expression.

Ethical approval for the use of animals in this study
-----------------------------------------------------

Although animals were used in this experimental work, no direct experiments were performed on them. Only blood (approximately 20 ml/animal) was collected to detect MAP and mutations. The experiment was neither related with the stem-cell research. Thus no approval from the ethics committee is necessary.
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